Biomarkers for early detection and screening in pancreatic cancer: Highlights from the "45th ASCO Annual Meeting". Orlando, FL, USA. May 29 - June 2, 2009

Christopher J. Hoimes, Matthew Moyer, Muhammad Wasif Saif

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Pancreatic cancer is the second most frequent gastrointestinal malignancy with an unabated mortality that reflects the advanced stage of presentation. Detection of early disease through screening likely is the best way to meaningfully prolong survival. The development of biomarkers for screening holds enormous promise for increasing early detection and impacting mortality. Many biomarkers have been studied including the serum protein carbohydrate antigen 19-9, vascular endothelial growth factor, and nuclear factor kappa B, however, still no blood test or other fluid analysis reliably predicts patients with disease. The authors review abstracts from the 2009 annual meeting of the American Society of Clinical Oncology, Orlando, FL, U.S.A., that report evidence for early detection using a salivary biomarker array (#4630); a mucin epitope to PAM4 (#4613); a plasma nucleotide marker of hypoxia, miR-210 (#4624); and a cleavage product of complement pathway component C3b, iC3b (#4626). The meeting featured pancreatic cancer in over 100 research abstracts, of which, four are reviewed that focus on potential markers for early detection. When applied to a population of high risk patients, biomarkers of early pancreatic cancer could provide a minimally invasive way of identifying patients that require further evaluation using endoscopic tools. These molecular beacons may even be found to be sufficiently sensitive, specific, and cost effective to be applied to a broader population of patients.

Original languageEnglish (US)
Pages (from-to)352-356
Number of pages5
JournalJournal of the Pancreas
Volume10
Issue number4
StatePublished - Aug 19 2009

Fingerprint

Pancreatic Neoplasms
Biomarkers
Complement C3b
Mortality
NF-kappa B
Hematologic Tests
Mucins
Vascular Endothelial Growth Factor A
Population
Blood Proteins
Epitopes
Early Diagnosis
Nucleotides
Carbohydrates
Antigens
Costs and Cost Analysis
Survival
Research
Neoplasms

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

@article{fb4a52bd665e4e85914541a72abc2bdd,
title = "Biomarkers for early detection and screening in pancreatic cancer: Highlights from the {"}45th ASCO Annual Meeting{"}. Orlando, FL, USA. May 29 - June 2, 2009",
abstract = "Pancreatic cancer is the second most frequent gastrointestinal malignancy with an unabated mortality that reflects the advanced stage of presentation. Detection of early disease through screening likely is the best way to meaningfully prolong survival. The development of biomarkers for screening holds enormous promise for increasing early detection and impacting mortality. Many biomarkers have been studied including the serum protein carbohydrate antigen 19-9, vascular endothelial growth factor, and nuclear factor kappa B, however, still no blood test or other fluid analysis reliably predicts patients with disease. The authors review abstracts from the 2009 annual meeting of the American Society of Clinical Oncology, Orlando, FL, U.S.A., that report evidence for early detection using a salivary biomarker array (#4630); a mucin epitope to PAM4 (#4613); a plasma nucleotide marker of hypoxia, miR-210 (#4624); and a cleavage product of complement pathway component C3b, iC3b (#4626). The meeting featured pancreatic cancer in over 100 research abstracts, of which, four are reviewed that focus on potential markers for early detection. When applied to a population of high risk patients, biomarkers of early pancreatic cancer could provide a minimally invasive way of identifying patients that require further evaluation using endoscopic tools. These molecular beacons may even be found to be sufficiently sensitive, specific, and cost effective to be applied to a broader population of patients.",
author = "Hoimes, {Christopher J.} and Matthew Moyer and Saif, {Muhammad Wasif}",
year = "2009",
month = "8",
day = "19",
language = "English (US)",
volume = "10",
pages = "352--356",
journal = "Journal of the Pancreas",
issn = "1590-8577",
publisher = "E.S. Burioni Ricerche Bibliografiche",
number = "4",

}

Biomarkers for early detection and screening in pancreatic cancer : Highlights from the "45th ASCO Annual Meeting". Orlando, FL, USA. May 29 - June 2, 2009. / Hoimes, Christopher J.; Moyer, Matthew; Saif, Muhammad Wasif.

In: Journal of the Pancreas, Vol. 10, No. 4, 19.08.2009, p. 352-356.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Biomarkers for early detection and screening in pancreatic cancer

T2 - Highlights from the "45th ASCO Annual Meeting". Orlando, FL, USA. May 29 - June 2, 2009

AU - Hoimes, Christopher J.

AU - Moyer, Matthew

AU - Saif, Muhammad Wasif

PY - 2009/8/19

Y1 - 2009/8/19

N2 - Pancreatic cancer is the second most frequent gastrointestinal malignancy with an unabated mortality that reflects the advanced stage of presentation. Detection of early disease through screening likely is the best way to meaningfully prolong survival. The development of biomarkers for screening holds enormous promise for increasing early detection and impacting mortality. Many biomarkers have been studied including the serum protein carbohydrate antigen 19-9, vascular endothelial growth factor, and nuclear factor kappa B, however, still no blood test or other fluid analysis reliably predicts patients with disease. The authors review abstracts from the 2009 annual meeting of the American Society of Clinical Oncology, Orlando, FL, U.S.A., that report evidence for early detection using a salivary biomarker array (#4630); a mucin epitope to PAM4 (#4613); a plasma nucleotide marker of hypoxia, miR-210 (#4624); and a cleavage product of complement pathway component C3b, iC3b (#4626). The meeting featured pancreatic cancer in over 100 research abstracts, of which, four are reviewed that focus on potential markers for early detection. When applied to a population of high risk patients, biomarkers of early pancreatic cancer could provide a minimally invasive way of identifying patients that require further evaluation using endoscopic tools. These molecular beacons may even be found to be sufficiently sensitive, specific, and cost effective to be applied to a broader population of patients.

AB - Pancreatic cancer is the second most frequent gastrointestinal malignancy with an unabated mortality that reflects the advanced stage of presentation. Detection of early disease through screening likely is the best way to meaningfully prolong survival. The development of biomarkers for screening holds enormous promise for increasing early detection and impacting mortality. Many biomarkers have been studied including the serum protein carbohydrate antigen 19-9, vascular endothelial growth factor, and nuclear factor kappa B, however, still no blood test or other fluid analysis reliably predicts patients with disease. The authors review abstracts from the 2009 annual meeting of the American Society of Clinical Oncology, Orlando, FL, U.S.A., that report evidence for early detection using a salivary biomarker array (#4630); a mucin epitope to PAM4 (#4613); a plasma nucleotide marker of hypoxia, miR-210 (#4624); and a cleavage product of complement pathway component C3b, iC3b (#4626). The meeting featured pancreatic cancer in over 100 research abstracts, of which, four are reviewed that focus on potential markers for early detection. When applied to a population of high risk patients, biomarkers of early pancreatic cancer could provide a minimally invasive way of identifying patients that require further evaluation using endoscopic tools. These molecular beacons may even be found to be sufficiently sensitive, specific, and cost effective to be applied to a broader population of patients.

UR - http://www.scopus.com/inward/record.url?scp=68649124823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68649124823&partnerID=8YFLogxK

M3 - Article

C2 - 19581733

AN - SCOPUS:68649124823

VL - 10

SP - 352

EP - 356

JO - Journal of the Pancreas

JF - Journal of the Pancreas

SN - 1590-8577

IS - 4

ER -